JP2023518596A5 - - Google Patents
Info
- Publication number
- JP2023518596A5 JP2023518596A5 JP2022558063A JP2022558063A JP2023518596A5 JP 2023518596 A5 JP2023518596 A5 JP 2023518596A5 JP 2022558063 A JP2022558063 A JP 2022558063A JP 2022558063 A JP2022558063 A JP 2022558063A JP 2023518596 A5 JP2023518596 A5 JP 2023518596A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- protein
- polynucleotide
- split
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382236.6A EP3885440A1 (en) | 2020-03-26 | 2020-03-26 | Split inteins and their uses |
| EP20382236.6 | 2020-03-26 | ||
| PCT/EP2021/058016 WO2021191447A1 (en) | 2020-03-26 | 2021-03-26 | Split inteins and their uses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026080696A Division JP2026130000A (ja) | 2020-03-26 | 2026-05-13 | スプリットインテイン及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023518596A JP2023518596A (ja) | 2023-05-02 |
| JP2023518596A5 true JP2023518596A5 (enExample) | 2024-04-05 |
| JP7867703B2 JP7867703B2 (ja) | 2026-06-01 |
Family
ID=70292931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022558063A Active JP7867703B2 (ja) | 2020-03-26 | 2021-03-26 | スプリットインテイン及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230116688A1 (enExample) |
| EP (2) | EP3885440A1 (enExample) |
| JP (1) | JP7867703B2 (enExample) |
| KR (1) | KR20220160052A (enExample) |
| CN (1) | CN115698307A (enExample) |
| AU (1) | AU2021241899A1 (enExample) |
| BR (1) | BR112022019167A2 (enExample) |
| CA (1) | CA3175696A1 (enExample) |
| IL (1) | IL296712A (enExample) |
| WO (1) | WO2021191447A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL325122A (en) | 2018-02-22 | 2026-02-01 | Akouos Inc | Compositions and methods for treating non-age-related hearing impairment in humans |
| KR20210055733A (ko) | 2018-09-07 | 2021-05-17 | 빔 테라퓨틱스, 인크. | 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법 |
| WO2021040703A1 (en) * | 2019-08-28 | 2021-03-04 | The Trustees Of Princeton University | Atypical split inteins and uses thereof |
| CA3168055A1 (en) | 2020-02-21 | 2021-08-26 | Emmanuel John Simons | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
| US20250319126A1 (en) * | 2021-10-29 | 2025-10-16 | Shanghai Sinobay Biotechnology Co., Ltd. | Condition-controlled spliceable chimeric antigen receptor molecule and application thereof |
| CN117106824B (zh) * | 2022-05-17 | 2025-09-02 | 上海佑音医药生物科技有限公司 | 一种治疗听力损伤的双载体系统及其应用 |
| KR20250141200A (ko) * | 2023-02-01 | 2025-09-26 | 알렌 인스티튜트 | 전압-게이팅 나트륨 채널 기능의 인테인 매개 재구성 |
| EP4726045A1 (en) | 2023-06-07 | 2026-04-15 | Peking University Third Hospital (The Third Clinical Medical School of Peking University) | Expression cassette combination and use thereof |
| EP4762183A1 (en) * | 2023-08-16 | 2026-06-24 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Systems and methods for improving safety of split intein aav mediated gene therapy |
| CN121909039A (zh) | 2023-09-04 | 2026-04-21 | 斯普莱斯生物有限责任公司 | 分裂内含肽用于治疗scn1a相关疾病的用途 |
| WO2025153705A1 (en) | 2024-01-18 | 2025-07-24 | Splicebio, Sl | Use of split intein for the treatment of myo7a-associated disease |
| WO2025193938A1 (en) * | 2024-03-13 | 2025-09-18 | Oregon Health & Science University | Delivery of type iv collagen alpha chain using a split intein dual aav vector |
| WO2026013288A1 (en) | 2024-07-12 | 2026-01-15 | Splicebio, Sl | Split intein for use in the treatment of cep290-associated disease |
| WO2026057767A1 (en) | 2024-09-13 | 2026-03-19 | Splicebio, Sl | Use of split intein for the treatment of abca3-associated disease |
| WO2026109723A1 (en) * | 2024-11-22 | 2026-05-28 | Katholieke Universiteit Leuven | Efficient intein splicing in dual aav gene delivery |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US5100792A (en) | 1984-11-13 | 1992-03-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues |
| US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| FR2714830B1 (fr) | 1994-01-10 | 1996-03-22 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2715847B1 (fr) | 1994-02-08 | 1996-04-12 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2727679B1 (fr) | 1994-12-05 | 1997-01-03 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
| FR2730637B1 (fr) | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
| US8298818B2 (en) | 2006-04-28 | 2012-10-30 | University Of Florida Research Foundation, Inc. | Self-complementary adeno-associated virus having a truncated CMV-chicken β-actin promoter |
| CA2979120A1 (en) * | 2015-03-03 | 2016-09-09 | Fondazione Telethon | Multiple aav vector system for expressing genes over 5 kilobases, comprising at least one degradation signal and uses thereof |
| SG11201710569YA (en) * | 2015-06-19 | 2018-01-30 | Riken | pH-RESPONSIVE PROTEOLYSIS PROBE |
| WO2017132580A2 (en) * | 2016-01-29 | 2017-08-03 | The Trustees Of Princeton University | Split inteins with exceptional splicing activity |
| CA3116606A1 (en) | 2018-10-15 | 2020-04-23 | Fondazione Telethon | Intein proteins and uses thereof |
-
2020
- 2020-03-26 EP EP20382236.6A patent/EP3885440A1/en active Pending
-
2021
- 2021-03-26 KR KR1020227037261A patent/KR20220160052A/ko active Pending
- 2021-03-26 EP EP21713447.7A patent/EP4127194A1/en active Pending
- 2021-03-26 CN CN202180038835.4A patent/CN115698307A/zh active Pending
- 2021-03-26 JP JP2022558063A patent/JP7867703B2/ja active Active
- 2021-03-26 WO PCT/EP2021/058016 patent/WO2021191447A1/en not_active Ceased
- 2021-03-26 IL IL296712A patent/IL296712A/en unknown
- 2021-03-26 CA CA3175696A patent/CA3175696A1/en active Pending
- 2021-03-26 US US17/914,212 patent/US20230116688A1/en active Pending
- 2021-03-26 BR BR112022019167A patent/BR112022019167A2/pt unknown
- 2021-03-26 AU AU2021241899A patent/AU2021241899A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018537087A5 (enExample) | ||
| JP2018171063A5 (enExample) | ||
| JP2023506765A5 (enExample) | ||
| JP2019506166A5 (enExample) | ||
| JP2023504914A5 (enExample) | ||
| JP2019122392A5 (enExample) | ||
| EP3960756A1 (en) | Flagellin fusion protein and use thereof | |
| JP2011501951A5 (enExample) | ||
| JP2023528207A5 (enExample) | ||
| JP2023553697A5 (enExample) | ||
| JP2012505902A5 (enExample) | ||
| JP2014500724A5 (enExample) | ||
| DK2190863T3 (en) | New albumin binding compositions, methods and uses | |
| JP2023525752A5 (enExample) | ||
| JP2013517783A5 (enExample) | ||
| CA2901368A1 (en) | Csf1 therapeutics | |
| JP2020517260A5 (enExample) | ||
| JP2023512824A5 (enExample) | ||
| JP2024508683A5 (enExample) | ||
| JP2023545707A5 (enExample) | ||
| CN105658228B (zh) | 结合人类补体c5的稳定多肽 | |
| Li et al. | A novel method for purifying recombinant human host defense cathelicidin LL-37 by utilizing its inherent property of aggregation | |
| JP2020509737A5 (enExample) | ||
| JP2012516140A5 (enExample) | ||
| CN104844712A (zh) | 肺炎链球菌蛋白抗原及其制备方法和应用 |